文章：

基于抗体的蛋白质组学：肿瘤快速跟踪分子诊断

Antibody-based proteomics: fast-tracking molecular diagnostics in oncology

原文发布日期：2010-08-19

DOI: 10.1038/nrc2902

类型: Review Article

开放获取: 否

要点：

1. Personalization of cancer therapy requires the identification of unambiguous diagnostic, prognostic and predictive biomarkers to facilitate the accurate stratification of patients and the monitoring of responses to targeted therapies.
2. The systematic generation and validation of specific antibodies offers a high-throughput mechanism for the functional exploration of the proteome and a logical approach for fast-tracking the translation of identified biomarkers.
3. Multiple approaches exist, each with specific characteristics and advantages that are suitable for a wide range of applications, which capitalize on the inherent specificity and sensitivity of antibodies as affinity reagents.
4. The integration of antibody-based approaches with existing genomic and transcriptomic methods offers huge potential, and the clinical implementation of new high-throughput antibody-based approaches will depend on the integration of data across various platforms.
5. The clinical application of new antibody-based assays demonstrates their utility as accurate, sensitive and robust diagnostic and prognostic tests and has led to the development of a new approach, known as pathway diagnostics, which is likely to have a crucial role in the design of future molecular therapeutic trials.

要点翻译：

1. 癌症治疗的个体化需要明确诊断性、预后性和预测性生物标志物的鉴定，以促进患者的准确分层和靶向治疗反应的监测。
2. 特异性抗体的系统化生成与验证为蛋白质组的功能探索提供了高通量机制，并为快速转化已识别生物标志物提供了合乎逻辑的路径。
3. 现有多种方法各具特色与优势，适用于广泛的应用场景，这些方法充分发挥了抗体作为亲和试剂的固有特异性和敏感性。
4. 基于抗体的研究方法与现有基因组学、转录组学技术的整合展现出巨大潜力，而新型高通量抗体技术在临床实践中的应用将取决于跨平台数据的整合。
5. 新型抗体检测方法的临床应用证明了其作为精准、灵敏、稳定的诊断与预后检测工具的价值，并催生了被称为"通路诊断"的新方法，该方法很可能在未来分子治疗试验的设计中发挥关键作用。

英文摘要：

The effective implementation of personalized cancer therapeutic regimens depends on the successful identification and translation of informative biomarkers to aid clinical decision making. Antibody-based proteomics occupies a pivotal space in the cancer biomarker discovery and validation pipeline, facilitating the high-throughput evaluation of candidate markers. Although the clinical utility of these emerging technologies remains to be established, the traditional use of antibodies as affinity reagents in clinical diagnostic and predictive assays suggests that the rapid translation of such approaches is an achievable goal. Furthermore, in combination with, or as alternatives to, genomic and transcriptomic methods for patient stratification, antibody-based proteomics approaches offer the promise of additional insight into cancer disease states. In this Review, we discuss the current status of antibody-based proteomics and its contribution to the development of new assays that are crucial for the realization of individualized cancer therapy.

摘要翻译： 

个性化癌症治疗方案的有效实施，依赖于能够成功鉴定并转化出有价值的生物标志物，以辅助临床决策。基于抗体的蛋白质组学在癌症生物标志物的发现与验证流程中占据关键地位，可实现对候选标志物的高通量评估。尽管这些新兴技术的临床效用尚待确立，但抗体在临床诊断和预测性检测中作为亲和试剂的传统应用表明，此类方法的快速转化是一个可实现的目标。此外，基于抗体的蛋白质组学方法可作为基因组学和转录组学方法用于患者分层的补充或替代，有望为癌症疾病状态提供更深层次的洞察。本文综述了基于抗体的蛋白质组学的现状，及其对开发新型检测方法、实现个体化癌症治疗所做出的重要贡献。

原文链接：

Antibody-based proteomics: fast-tracking molecular diagnostics in oncology